Loading...

Biotinylated Recombinant Human BTLA-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
CD272, B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein
Ave. Rating
Submit a Review
Product Citations
publications
Biotinylated recombinant human BTLA-Fc chimera binds to immobilized recombinant mouse HVEM at 0.05 µg/mL in a dose-dependent manner. The ED50 for this effect is 0.5 - 2.0 ng/mL.
  • Biotinylated recombinant human BTLA-Fc chimera binds to immobilized recombinant mouse HVEM at 0.05 µg/mL in a dose-dependent manner. The ED50 for this effect is 0.5 - 2.0 ng/mL.
  • Stability Testing for Biotinylated Recombinant Human BTLA-Fc Chimera. Biotinylated recombinant human BTLA-Fc chimera was aliquoted in PBS, pH 7 at 0.2 mg/mL and one aliquot was kept at 4°C (Control), and another was frozen and thawed four times (4x Freeze/Thaw). After this procedure, the samples were tested for their ability to bind to immobilized recombinant mouse HVEM at 0.05 µg/mL in a dose-dependent manner. The ED50 for this effect is 0.5 - 2.0 ng/mL.
Cat # Size Price Quantity Check Availability Save
794904 25 µg $288
Check Availability


Need larger quantities of this item?
Request Bulk Quote
794906 100 µg $856
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

BTLA (B and T lymphocyte attenuator, CD272) is a type I transmembrane glycoprotein with four extracellular cysteine-rich domains. It is an inhibitory molecule structurally and functionally similar to cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1).  These molecules belong to the immunoglobulin superfamily that binds B7 family members. Different from CTLA-4 and PD-1 binding with the B7 family members, BTLA interacts with herpes virus entry mediator (HVEM/TNFRSF14) which belongs to TNFR family. BTLA/HVEM interaction was the first demonstration of crosstalk between these two family members.  BTLA/HVEM interaction limits T cell activity in vivo and regulates the homeostatic expansion of CD4+ and CD8+ T cells. BTLA/HVEM interaction negatively modulates T cell activation. HVEM induces BTLA tyrosine phosphorylation and inhibits T-cell proliferation.  There is accumulating evidence suggesting that BTLA/HVEM signaling also plays an important role in autoimmunity and infection at mucosal surfaces. The BTLA/HVEM interaction does not prevent the simultaneous binding of other HVEM ligands such as LIGHT/TNFSF14 or Lymphotoxin-alpha. BTLA is expressed on T cells, B cells, macrophages, dendritic cells, and natural killer cells. Constitutive expression level of BTLA on resting T cells are very low, but increase after the activation of T cells. BTLA is highly expressed on resting B cells.

Product Details
Technical data sheet

Product Details

Source
Human BTLA, amino acid (Lys31-Trp153) (Accession: Q7Z6A9.3), with a linker (GS), a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in CHO cells. Human BLTA-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 371 amino acid recombinant protein has a predicted molecular mass of approximately 42 kD. The DTT-reduced and non-reduced protein migrates at approximately 60 kD and 110 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Lys.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE
Formulation
0.22 µm filtered protein solution is in pH 7.2, PBS, 5% glycerol.
Endotoxin Level
Less than 0.1 EU per µg protein as determined by the LAL method
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2ᵒC and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Biotinylated recombinant human BTLA-Fc chimera binds to immobilized recombinant mouse HVEM at 0.05 µg/mL in a dose-dependent manner. The ED50 for this effect is 0.5 - 2.0 ng/mL.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Disulfide bond-linked homodimer
Distribution

Expressed in activated B, T (activated, memory), Th1, Th2 and Th17 Effector T-cells of patients with systemic lupus erythematosus, dendritic cells, macrophages, and hematopoietic stem cells 

Function
B cell co-stimulation, proliferation and Ig production, limits T cell activity in vivo and homeostatic expansion of CD4+ and CD8+ T cells, NKT differentiation
Interaction
Lymphocytes
Ligand/Receptor
HVEM (TNFRSF14)
Bioactivity
Biotinylated recombinant human BTLA-Fc chimera binds to immobilized recombinant mouse HVEM in a dose-dependent manner.
Antigen References

Watanabe N, et al. 2003. Nat. Immunol. 4:670.
1. Gavrieli M, et al. 2003. Biochem. Biophys. Res. Commun. 312:1236.
2. Gonzalez LC, et al. 2005. Proc. Natl. Acad. Sci. USA 102:1116.
3. Sedy JR, et al. 2005. Nat. Immunol. 6:90.
4. Kronenberg KM, et al., 2009. Proc. Natl. Acad. Sci. USA 106:6244.
5. Shui JW, et al., 2011. J. Leukoc. Biol. 89:517
6. Ofter C, et al., 2019, Int. J. Mol. Sci.  20:4505.
7. Yu X, et al., 2019. Front. Immunol. 10: 617.

Gene ID
151888 View all products for this Gene ID
UniProt
View information about BTLA on UniProt.org
Go To Top Version: 1    Revision Date: 03/23/2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account